Elevance Health Inc.
ELV · NYSE
Financial statements
Annual and quarterly income, balance-sheet, cash-flow and key-statistics data.
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2022 FY | 156.60B | 39.95B | 8.45B | 5.89B | 24.56 |
| 2023 FY | 171.34B | 47.01B | 8.75B | 5.99B | 25.38 |
| 2024 FY | 176.81B | 49.24B | 8.89B | 5.98B | 25.81 |
| 2025 FY | 199.13B | 50.90B | 8.11B | 5.66B | 25.18 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2022 FY | 102.76B | 66.43B | 7.39B | 25.80B | 36.24B |
| 2023 FY | 108.93B | 69.52B | 6.53B | 26.65B | 39.31B |
| 2024 FY | 116.89B | 75.46B | 8.29B | 32.70B | 41.32B |
| 2025 FY | 121.49B | 77.47B | 9.49B | 33.24B | 43.88B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2022 FY | 8.40B | -1.15B | 7.25B | -1.23B | 2.51B |
| 2023 FY | 8.06B | -1.30B | 6.77B | -1.40B | -861.00M |
| 2024 FY | 5.81B | -1.26B | 4.55B | -1.51B | 1.76B |
| 2025 FY | 4.29B | -1.12B | 3.17B | -1.53B | 1.20B |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2022 FY | 123.11B | 141.52B | — | — | — |
| 2023 FY | 109.91B | 130.03B | — | — | — |
| 2024 FY | 85.90B | 110.32B | — | — | — |
| 2025 FY | 77.75B | 101.50B | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-12-31 | — | — | — | — | — |
| 2028-12-31 | — | — | — | — | — |
Income statement
| Period | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 Q3 | 50.71B | 12.57B | 1.76B | 1.19B | 5.32 |
| 2025 Q4 | 49.75B | 11.68B | 581.00M | 547.00M | 2.47 |
| 2026 Q1 | 50.18B | 9.10B | 2.66B | 1.76B | 8.00 |
| 2026 Q2 | 50.47B | 44.98B | 2.06B | 1.46B | 6.71 |
Balance sheet
| Period | Total assets | Liabilities | Cash | Debt | Equity |
|---|---|---|---|---|---|
| 2025 Q3 | 122.75B | 78.67B | 8.71B | 32.10B | 43.95B |
| 2025 Q4 | 121.49B | 77.47B | 9.49B | 33.24B | 43.88B |
| 2026 Q1 | 125.83B | 81.79B | 9.66B | 31.84B | 43.90B |
| 2026 Q2 | 126.44B | 81.42B | 10.23B | 31.04B | 44.88B |
Cash flow
| Period | Operating cash flow | Capital expenditure | Free cash flow | Dividends paid | Net cash change |
|---|---|---|---|---|---|
| 2025 Q3 | 1.14B | -360.00M | 775.00M | -381.00M | 153.00M |
| 2025 Q4 | 84.00M | -293.00M | -209.00M | -377.00M | 778.00M |
| 2026 Q1 | 4.33B | -235.00M | 4.10B | -376.00M | 166.00M |
| 2026 Q2 | 1.91B | -287.00M | 1.63B | -373.00M | 575.00M |
Key statistics
| Period | Market cap | Enterprise value | P/E | Price / sales | Debt / equity |
|---|---|---|---|---|---|
| 2025 Q3 | 72.96B | 96.35B | — | — | — |
| 2025 Q4 | 77.75B | 101.50B | — | — | — |
| 2026 Q1 | 64.55B | 86.74B | — | — | — |
| 2026 Q2 | 84.27B | 105.08B | — | — | — |
| 2026-09-30 | — | — | — | — | — |
| 2026-12-31 | — | — | — | — | — |
| 2027-03-31 | — | — | — | — | — |